ACHL Stock Summary and Trading Ideas (Achilles Therapeutics PLC - American Depositary Shares | NASDAQ:ACHL)

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol ACHL.

As of July 26, 2024, ACHL stock price declined to $0.83 with 20,401 million shares trading.

ACHL has a beta of 1.42, meaning it tends to be more sensitive to market movements. ACHL has a correlation of 0.06 to the broad based SPY ETF.

ACHL has a market cap of $35.40 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ACHL stock traded as high as $11.40 and as low as $.74.

ACHL has underperformed the market in the last year with a return of -20.3%, while the SPY ETF gained +21.0%. In the last 3 month period, ACHL fell short of the market, returning +7.0%, while SPY returned +8.5%. However, in the most recent 2 weeks ACHL has outperformed the stock market by returning -1.3%, while SPY returned -2.2%.

ACHL support price is $.81 and resistance is $.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACHL stock will trade within this expected range on the day.